Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (571-580 of 754) with videos related to

Pageof 76
Sort By:
American Heart Journal|July 6, 2010
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)Faisal Shamshad, Satish Kenchaiah, Peter V Finn, et al.
International Journal of Cardiology|December 1, 2012
Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANTSally C Inglis, Judith Bebchuk, Sultan A Al-Suhaim, et al.
Journal of the American Heart Association|February 8, 2022
Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort StudyDaniel Modin, Brian Claggett, Mads Emil Jørgensen, et al.
American Heart Journal|July 11, 2006
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothRajesh Janardhanan, Satish Kenchaiah, Eric J Velazquez, et al.
Circulation. Heart Failure|March 11, 2016
Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist TrialEldrin F Lewis, Hae-Young Kim, Brian Claggett, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 4, 2014
Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist deviceDeepak K Gupta, Hicham Skali, Jose Rivero, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 21, 2016
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
The New England Journal of Medicine|September 3, 2009
Cardiac-resynchronization therapy for the prevention of heart-failure eventsArthur J Moss, W Jackson Hall, David S Cannom, et al.
European Stroke Journal|April 23, 2019
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANTAzmil H Abdul-Rahim, Kieran F Docherty, Hicham Skali, et al.
Circulation|June 22, 2005
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarctionScott D Solomon, Hicham Skali, Nagesh S Anavekar, et al.
Pageof 76

Showing results (571-580 of 754) with videos related to

Sort By:
Pageof 76
American Heart Journal|July 6, 2010
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)Faisal Shamshad, Satish Kenchaiah, Peter V Finn, et al.
International Journal of Cardiology|December 1, 2012
Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANTSally C Inglis, Judith Bebchuk, Sultan A Al-Suhaim, et al.
Journal of the American Heart Association|February 8, 2022
Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort StudyDaniel Modin, Brian Claggett, Mads Emil Jørgensen, et al.
American Heart Journal|July 11, 2006
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothRajesh Janardhanan, Satish Kenchaiah, Eric J Velazquez, et al.
Circulation. Heart Failure|March 11, 2016
Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist TrialEldrin F Lewis, Hae-Young Kim, Brian Claggett, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 4, 2014
Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist deviceDeepak K Gupta, Hicham Skali, Jose Rivero, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 21, 2016
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
The New England Journal of Medicine|September 3, 2009
Cardiac-resynchronization therapy for the prevention of heart-failure eventsArthur J Moss, W Jackson Hall, David S Cannom, et al.
European Stroke Journal|April 23, 2019
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANTAzmil H Abdul-Rahim, Kieran F Docherty, Hicham Skali, et al.
Circulation|June 22, 2005
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarctionScott D Solomon, Hicham Skali, Nagesh S Anavekar, et al.
Pageof 76